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Abstract BACKGROUND: The coincidence of autoimmune thyroiditis (AIT) in patients with 
papillary thyroid carcinoma (PTC) is ranging between 10 and 58% in the general 
population. 
MATERIAL AND METHODS: In the present study retrospective ultrasound, clini-
cal and autoimmune assessment of 24 patients diagnosed with papillary thyroid 
carcinoma between 2000–2016 was performed. 
RESULTS: The coexistence of PTC and AIT was found in 50% of patients with 
PTC. Patients were divided into two groups. PTC AIT (+) group involved 12 
children at the mean age 14.9 years (range 11–20 years, 9 girls) and PTC AIT 
(–) 12 children at the mean age 12.9 years (range 7–18 years, 5 girls). Papillary 
thyroid microcarcinoma (PTMC) was diagnosed in 6 patients (in 5 with AIT). US 
characteristics of PTC was heterogenous: hypoechogenic with/without increased 
vascularisation, normoechogenic with halo, with/without microcalcifications. In 
70% PTC AIT (+) and in all PTC AIT (–) patients ultrasound analysis revealed 
that the thyroid tissue of the whole gland was normoechogenic. Local metastases 
in lymph nodes were found in 40% of PTMC AIT (+). 
CONCLUSION: Lack of increased vascularization and microcalcifications and pres-
ence of``halo`in the nodule does not exclude malignancy. Due to the presence of 
lymph node involvement in PTMC in all children with PTC total thyroidectomy 
should be performed with lymph nodes verification. 
 
Abbreviations:
DTC - differentiated thyroid carcinoma
PTC - papillary thyroid carcinoma
PTMC - papillary thyroid microcarcinoma
AIT - autoimmune thyroiditis
AITD - autoimmune thyroid disease
FNAB - fine needle aspiration biopsy
aTPO - thyroperoxidase antibody
aTG - thyroglobulin antibody
TRab - TSH receptor antibody
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INTRODUCTION
Autoimmune thyroid disease (AITD) is the most 
common cause of acquired thyroid disease in pediatric 
patients (Zdraveska & Kocova 2012). The frequency of 
AITD is rising and has been reported between 0.3–2% 
in children and 4–9.6% in adolescents (Zois et al. 2003). 
Papillary thyroid carcinoma (PTC) accounts for 90% or 
more of all childhood differentiated thyroid carcinoma 
(DTC) cases (Niedziela et al. 2016). The prevalence 
of PTC, especially papillary thyroid microcarcinoma 
(PTMC) is rising in the last years partly due to more 
frequent ultrasound (US) assessments and US con-
trolled fine needle aspiration biopsy (FNAB) of small 
nodules of the thyroid gland.
In the first report on the coincidence of thyroid 
cancer and AIT Dailey et al. (1955) postulated that 
AIT might be considered a precancerous lesion. Other 
researchers reported a coincidence of AIT in PTC rang-
ing from 10–58% in the general population (Ott et al. 
1985; Carson et al. 1996; Schaffler et al. 1998; Niedziela et 
al. 2006; Jankovic et al. 2013). In pediatric patients with 
DTC the coincidence of AIT is ranging from 6.3–43% 
depending on the patients selection (Danese et al. 1997; 
Corrias et al. 2008; O`Groman et al. 2010; Park et al. 
2013; Iliadou et al. 2015). In a large case series presented 
by Corrias et al. (2008) thyroid nodules were found in 
115 of 365 patients with AIT (31.5%), with 11/115 cases 
of PTC (9.6%). In a large study including 108 children 
IIliadou et al. (2015) have found that 28.6% of the 
patients with DTC (in 93.5 % with PTC) presented AIT. 
In the last years there is an increase of coincidence 
of AIT and PTC. In adult patients with PTC, the preva-
lence of chronic lymphocytic thyroiditis increased 
four-fold in men and two-fold in women between 1999 
and 2008 (Oh et al. 2014). In pediatric patients with 
PTC Niedziela et al. (2015) found that the prevalence 
of chronic lymphocytic thyroiditis increased ten-fold 
between 1996–2000 and 2001–2015 years.
According to the current pediatric guidelines neck 
US should be performed at least every 12 months in 
children with autoimmune thyroid disease (Niedziela 
et al. 2016). 
The aim of the present study is ultrasound, clinical 
and autoimmune characterization of patients with pap-
illary thyroid carcinoma.
SUBJECTS AND METHODS
Subjects
Retrospective analysis of medical records and thyroid 
ultrasound results of 24 patients diagnosed with PTC 
between 2000 and 2016 in the major tertiary pediat-
ric endocrinology center was performed. The analysis 
included age at diagnosis, gender, the cause of refer-
ral to the endocrinologist, thyroid status (euthyroid, 
hypothyroid, hyperthyroid), levels of autoantibodies 
(aTPO assessed in 24 patients, aTG in 5 patients, TRab 
in 3 patients) and ultrasound features of the malignant 
nodule and the thyroid gland surrounding the nodule. 
Postoperative staging was done based on the tumour, 
nodes and metastases (TNM) system proposed by the 
American Joint Committee on Cancer (Ito et al. 2010).
Patients were divided into two groups. PTC AIT 
(+) group involved 12 children at the mean age 14.9 
years (range 11–20 years, 9 girls). PTC AIT (–) group 
involved 12 children at the mean age 12.9 years (range 
7–18 years, 5 girls). 
Methods
AITD was diagnosed based on clinical (presence of 
goiter, firm consistency of the thyroid gland), hormonal 
(hypothyroidism or thyreotoxicosis), typical features of 
chronic autoimmune thyroiditis on thyroid ultrasound 
assessment and increased aTPO, and/or aTG and/or 
TRab antibodies levels. AIT was diagnosed in euthy-
roid patients with an increased aTPO and/or aTG and/
or TRab antibodies levels. PTMC was diagnosed after 
FNAB fulfilling Bethesda criteria (Cibas et al. 2009), 
and if on US assessment its diameter was ≤10 mm. In 
patients with PTC total thyroidectomy with lateral and 
central lymph nodes histopathological verification was 
performed. 
The study was approved by the Institutional Review 
Board.
RESULTS
From 2000 to 2016 we had the total number of 24 cases 
of PTC in children treated in our center (Table 1). In the 
last two years an increase of newly diagnosed small PTC 
of diameter below 10 mm was observed, that may be 
associated with more frequent ultrasound assessment 
of patients in this time period, every 6 to 12 months 
(Table 1).
The coexistence of PTC with AIT was found in 50% 
(12/24) of patients and there was also an increase in the 
last two years (Table 1). In two patients: one AIT (+) 
and one AIT (–) PTC developed 7 and 13 years after 
prophylactic central nervous system irradiation due to 
acute lymphoblastic leukemia and in one patient AIT 
(–) 9 years after chest irradiation due to Wilms’ tumor 
(Table 1). In patient 11 PTC AIT (+) diabetes mellitus 
type 1 was diagnosed 5 years prior to PTC. 
Thyroid status analysis of patients with PTC and 
AIT (+) at presentation found that 1 patient presented 
with thyrotoxicosis, 5 with subclinical (compensated 
hypothyroiditis) and 6 were euthyroid. 11 patients with 
PTC AIT (–) were euthyroid and 1 presented with com-
pensated hypothyreosis (Table 1). 
Analysis of the whole group of 24 PTC revealed that 
patients with PTC AIT (+) when compared to patients 
with PTC AIT (–) were older (14.9 vs 12.9 years, ns), 
females predominated (75% vs 41.6%), 5 micro PTC 
(41.6%) were detected (mean diameter 8.4 mm) vs. 
1 microPTC in AIT (–) patients, the lymph node 
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involvement reached 58.3% (vs 91.6%), mean TSH 
(after excluding a patient with thyrotoxicosis at pre-
sentation) was higher (3.2 vs 2.3 uIU/ml). The cause 
of referral to the endocrinologist in PTC AIT (+) was a 
goiter in 7/12 (58.3%), a nodule found on ultrasound in 
4/12 (33.3%) and in 1 patient lymph nodes enlargement 
(8.3%). In PTC AIT (–) the cause of referral was also 
a goiter in 7/12 (58.3%) patients, in 3/12 (25%) lymph 
nodes enlargement and a nodule found on US in 2/12 
(16.7%). Three patients were referred to the hematol-
ogy unit first because of lymphadenopathy at presenta-
tion and the suspicion of Hodgkin lymphoma.
In patients with PTC AIT (+) the mean aTPO level 
assessed in 12 patients was 1823.6 IU/ml (range from 
Tab. 1. Clinical characterisation of patients.
 Age
yrs
Ca use of 
referral
Thyr oid US
PTC( mm)
TNM PTC vari ant
131 J
ther apy
aTPO
IU/ml
N <30 
aTG
U/ml
N<30
TRAb
IU/l
N<1 
TSH
uIU/ml
N:0.4-
 4.0
fT3
pmol/l
N:3.6-8. 6 
fT4
pmol/l
N:10-25 
AIT (+)
1 12 Goiter 20 PT1bN1bM0 follicular + 70.7 2.41 7.06 18
2 20 US 10 PT1aN1bM0
7 years aft er 
prophyl actic brain 
irradiation
classic + 722.5 0.64 5.72 12.9
3 14 Goiter 15×20 PT1bN1bM0 follicular + 1828 4.71 13.1
4 13 Goiter 31×39 PT2N1bM1 classic + 726.6 3.21 5.4 17.2
5 18 Goiter 13 pT1bN0M0 classic + <30 <20 5.2 0.02 13.4 31.6
6 17 US 21×16×26 PT2N1bM0  follicular + 853.4 0.7 1.02 16.9
7 13 Lymph node 
enlargement
23 PT3N1bM1 diffuse sclerosing + >9000 >8000 1.2 4.12 5.4 10.6
8 13 Goiter 8×8×9 PT1aN1aM0  classic /follicular + 126.2 154.3 5.05 7.1 20.2 
9 14 USG 7 and 2 PT1aN0M0 7 mm-classic/
solid 2 mm-f ollicular
- 1300 4.8 1.18
10 16 Goiter 6 PT1aN0M0  classic - 5911.2 300 2.12 15.5
11 17 USG 10 pT1aN0M0 classic - 1271.7 5.01 11.4
12 11 Goiter 12 pT1bN0M0 follicular with capsule - 42.94 43.39 2.01 1.31 
AIT (–)
13 7 Goiter 30 PT2N1bM0 classic/diffuse sclerosing/
solid /
clear cell /follicular
+ 11.6 1.83 6.9 12.2
14 16 USG n.a. PT1bN1bM0
13 years after 
prophyla ctic brain 
irradation
classic + - 1.44
15 16 Goiter 17 PT2N0Mx classic + - 2.4 13.4
16 18 Goiter 12×18 PT1bN1bM0 follicular + - 3.44 4.7 9.56
17 14 Lymph nodes 
enlargement
15×25 PT2N1bM0
9 years after chest 
irrada tion due  to 
Wilms tu
follicular + 15.7 2.05 4.8 19.2
18 17 Goiter 20×20 PT1bN1bM0 follicular + 26.2 2.1 5.8 17.2
19 7 Goiter 13×11.5×21 PT2N1bM0 diffuse sclerosing + 17.2 4.28 6.4 13.7
20 12 Lymph nodes 
enlargement
60×40 PT3N1bMx classic + 15.1 2.6 15.2
21 14 Goiter 12×13.1×17.6 PT1bN1bMx classic / follicular + - 3.03 5.79 11.4
22 10 Lymph nodes 
enlargement
40 PT3N1bMx solid with
focus of anaplastic
dedif ferentiation
+ - 0.6 3.9 16.3
23 15 USG 13×7 PT1bN1bM0 classic + <30 <20 1.7 4.1 1.03
24 9 Goiter 8×7.5×11 PT1bN0M0 follicular - <5.5 27.7 - 2.9 5.8 15.5
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<30 to >9000), mean aTG assessed in 5 patients was 
1703.5 U/ml (range<20 to >8000) and TRAb level 
assessed in 3 patients was 2.4 IU/l (range 0.7–5.2). The 
highest unmeasurable levels of aTPO >9000 IU/ml and 
aTG >8000 U/ml were found in a patient with diffuse 
sclerosing variant of PTC (Table 1).
In PTC AIT (+) we have been able to retrospec-
tively assess thyroid ultrasound images of 10 out of 12 
patients (83.3%). In 7/10 (70%) hypoechogenic PTC 
lesions were found (patients: 2,4,5,6,8,9,10), in 2/10 
normoechogenic with hypoechogenic ‘halo’ (patients: 
11,12) and in 1 patient with diffuse sclerosing PTC vari-
ant disseminated hyperechogenic lesions in the whole 
thyroid gland were found (patient 7). In 7/10 images no 
microcalcifications were visible on ultrasound images 
(2,6,10,8,9,11,12) and in 2/10 no increased vascularisa-
tion of the nodule was seen (patients: 8,9) (Figure 1).
In PTC AIT (–) patients we have been able to assess 
thyroid ultrasound images of 8 out of 12 patients (66.7%). 
In 4/8 irregular hypoechogenic PTC lesions with micro-
calcifications were found (patients: 13,18,20,21), in 
2/8 normo/hypoechogenic with hypoechogenic ‘halo’ 
without microcalcifications (patients:16,24) and in 1/8 
hypoechogenic without microcalcifications (patient: 
23). In patient 19 diffuse sclerosing PTC variant was 
confirmed after histopathology. In all except one lesion 
increased vascularisation was found (patient 23). In 
patient 22 CT scan was performed due to neck lymph 
node enlargement and Hodgkin lymphoma suspicion, 
histopathology of lymph node revealed PTC (Figure 2).
To summarise in 15/18 (83.3%) patients malignant 
nodule was found to be hypoechogenic on ultrasound 
imaging.
In 7/10 (70%) AIT (+) patients (2,6,8–12) ultrasound 
analysis revealed that the thyroid tissue of the whole 
gland was normoechogenic and in 4/7 of these patients 
(8,9,11,12) the thyroid tissue directly surrounding the 
PTC nodules (with diameter from 7 to 12 mm) was 
hyperechogenic forming like a `border` limiting the 
cancer (Figure 1).
In all PTC AIT (–) patients thyroid tissue of the 
whole gland outside the PTC nodule was normoecho-
genic. In the majority of patients PTC lesion was inva-
sive and the diameter was larger than in PTC AIT (+) 
(24.8 vs 15.9 mm, p<0.09).
In our series of patients uninodularity was more fre-
quent than multinodularity (patient 9).
PTC was suspected after first FNAB in 16/24 (66.7%) 
patients (1,3,5,6,8,9,11,13,14,16,17,18,19,20,21,23). PTC 
was suspected after second FNAB in one patient (4, 
4.2%). PTC was suspected after third FNAB in two 
patients (2,24;8.3%).
Fig. 1. Ultrasound features of PTC in AIT(+) patients.
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PTC was found after histopathological evaluation of 
removed thyroid gland in patients: 10 and 12 (8.3%). In 
patient 10 total thyroidectomy was performed due to 
large goiter (volume 55 ml) causing dyspnea and mul-
tinodularity (FNAB was benign twice). In patient 12 
FNAB was benign twice, total thyroidectomy was per-
formed due to multinodularity and increased diameter 
of nodules.
PTC was found in removed lymph node due to 
Hodgkin lymphoma suspicion in patients: 7,15,22 
(12.5%).
Following PTC variants were found: 13/24 (54.2%) 
– classic (in 3 patients also with other components: dif-
fuse sclerosing, solid, clear cell, follicular), 8/24 (33.3%) 
– follicular, 2/24 (8.3%) diffuse sclerosing and 1 patient 
– solid with anaplastic dedifferentiation (Table 1). His-
topathology revealed that above mentioned hyperecho-
genic border of PTMC seen on ultrasound was formed 
by fibrotic tissue, microcalcifications and foci of lym-
phocytic infiltration (patients 8,9,11,12) (Figure 3).
In PTC AIT (+) patients local metastases in neck 
lymph nodes were found in 7/12 patients (58.3%), in 
Fig. 2. Ultrasound features of PTC in AIT(–) patients.
Fig. 3. Histopathologyof PTMC in patient 9 AIT (+).The nodule and its border: 3A-HE×15-the nodule surrounded by a border, 3B-HE×40-the 
border, 3C-HE×40-the border. PTMC variants found in patient 9:3D-solid, 3E-classic, 3C-follicular.
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two also in the lungs and mediastinum. In 2/5 PTMC 
(40%) metastases in lymph nodes were found including 
one patient with microPTC of 9 x 8 x 8 mm dimensions 
with metastases found in as many as in 13/29 of lymph 
nodes assessed. In PTC AIT (–) patients local metasta-
ses in lymph nodes were found in 11/12 (91.7%).
Three patients PTC AIT (+) PT1aN0M0 (patients 
9,10,11) and one patient PTC AIT (–) PT1bN0M0 
(patient 24) were not treated with 131I therapy.
DISCUSSION
In this study, we presented the clinical and ultrasound 
characteristics of 24 pediatric patients with PTC with 
or without coincidence of autoimmune thyroiditis. 
The main cause of referral to the endocrinologist was a 
goiter in both groups. In 50% of patients autoimmune 
thyroiditis was diagnosed on the basis of a presence of 
an increased aTPO, aTG or TRab levels in serum. No 
PTC AIT (+) patient presented with an overt hypo-
thyroiditis, 50% were euthyroid and in 50% AITD 
was diagnosed (41.7% presented with compensated 
hypothyroiditis and one with hyperthyroiditis). Ultra-
sound analysis of the thyroid gland provided further 
useful diagnostic information. Among patients with 
thyroid cancer, hypoechogenic malignant nodules 
predominated (83%) over other ultrasound patterns. 
Whereas typically in AIT or AITD ultrasound imag-
ing reveals hypoechogenic thyroid gland due to more 
or less advanced lymphocytic infiltration that can 
be diffuse or focal, in our PTC cohort we observed 
that on ultrasound imaging inflammatory process in 
patients with PTC was not very advanced (Januś et al. 
2017). In 70% PTC AIT (+) patients ultrasound analy-
sis revealed that the thyroid tissue of the whole gland 
was normoechogenic and in 57.1% of these cases the 
thyroid tissue directly surrounding the PTC nodule 
was hyperechogenic forming like a `capsule/border` 
limiting the cancer. Histologically, in above men-
tioned cases, fibrosis, microcalcifications and foci of 
lymphocytic infiltration were found in this tissue. The 
question arises then if in these patients autoimmune 
thyroiditis is not secondary to the cancer. These data 
are supported by Paparodis et al. (2014) reports that 
the form of AITD pathology (destructive with clini-
cally overt hypothyroiditis vs. a less-destructive with 
clinically compensated hypothyroiditis or euthyroid) 
may play a role in differentiated thyroid cancer risk. 
Patients with less destructive AITD were described 
to have a higher risk for differentiated thyroid cancer 
than patients with destructive AITD (Paparodis et al. 
2014). These observations could provide a support for 
the hypothesis that autoimmune thyroiditis might be a 
secondary event (Januś et al. 2017).
According to Noureldine et al. (2015), recognition of 
AITD as a precursor or a risk factor for thyroid cancer 
in pediatric population, would have a high clinical 
impact, given that Hashimoto’s thyroiditis is not rare 
and its incidence is rising in children (Ehlers & Schott 
2014; Oh et al. 2014; Noureldine & Tufano 2015). It 
remains controversial whether autoimmune thyroiditis 
in children is a risk factor for developing PTC, is an 
incidental concurrent finding, or is a part of the host-
tumor response system (Ehlers & Schott 2014; Nourel-
dine & Tufano 2015).
Studies suggest that similar molecular mechanisms 
may influence early stages of oncogenesis and inflam-
mation in the thyroid gland (Ehlers & Schott 2014; 
Noureldine & Tufano,2015). As presented by Ehlers et 
al. (2014) TG and TPO represent the main target anti-
gens for cellular cytotoxic as well as humoral immune 
reactions (Ehlers & Schott 2014; Noureldine & Tufano 
2015). In addition to Paparodis et al. (2014) study 
presenting that elevated anti-TPO antibodies appear 
to protect against thyroid cancer in patients with HT 
we would like to highlight the diffuse sclerosing vari-
ant of PTC with local and distant metastases where we 
have found unmeasurable high values of both aTPO 
and aTG levels. As presented by Ehlers et al. (2014) 
tumor-protecting feature of TPO might be explained by 
(a) complement-mediated cell death, that is anti-TPO 
antibody-dependent because anti-Tg antibodies do not 
fix complement (Weetman 2004; Ehlers & Schott 2014), 
and (b) anti-TPO antibody-dependent cell toxicity due 
to the exclusive binding of anti-TPO antibodies to their 
effector cells via Fc-g receptor I (CD64) that is known 
to be expressed on monocytes (Rebuffat et al. 2008; 
Ehlers &Schott,2014).
By contrast, aTG seem to represent a risk factor for 
PTC (Grani et al. 2013; Ehlers & Schott 2014; Vasileia-
dis et al. 2014). One reason for this effect could be the 
fact that aTG from PTC patients recognize different TG 
epitopes than do aTG from patients with autoimmune 
thyroid diseases (HT and Graves’ disease) and from 
PTC patients with associated thyroiditis (Latrofa et al. 
2008; Ehlers &Schott,2014).
By analogy to autoimmune thyroiditis, TPO and TG 
also seem to represent the specific target antigens for 
the immune response in PTC (Ehlers & Schott 2014; 
Noureldine & Tufano 2015).Whether PTC develops 
despite autoimmunity or due to inflammation and 
preexisting autoimmunity, or whether AIT develops 
because of cross-reacting antitumor immunity, needs 
further research in pediatrics (Ehlers & Schott 2014).
From pathological perspective, it is important to dis-
tinguish between diffuse lymphocytic infiltration and 
focal peritumoral lymphocytic thyroiditis (Noureldine 
& Tufano, 2015). Hashimoto’s thyroiditis is a diffuse 
lymphocytic infiltration; therefore, it is considered an 
independent chronic process and does not signify a 
reaction to the tumor (Ehlers & Schott 2014; Nourel-
dine & Tufano 2015). The reactive alterations of stromal 
cells caused by the chronic inflammation may lead to 
cellular damage, thereby resulting in tumor develop-
ment (Buyukasik et al. 2011; Noureldine & Tufano 
2015). The reason for the induced antitumor immune 
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response might be the existence of yet undiagnosed 
papillary thyroid microcarcinomas (PTMC) (Ehlers 
& Schott 2014). In our study ultrasound imaging in 
4 patients PTC AIT (+), 3 of them with PTMC, is in 
favour for the latter category of the infiltration taking 
into account that the thyroid was normoechogenic and 
the direct tissue surrounding the nodule was hyper-
echogenic, `limiting` the lesion, and could be a part 
of peritumoral lymphocytic infiltration with positive 
antibodies detected in serum. PTMC is considered as 
the earlier stage of disease which eventually evolves into 
PTC, potentially triggered by growth factors, as genetic 
studies revealed similar gene expression profiles in 
PTMC and PTC (Kim et al. 2010; Saranac et al. 2011). 
Possibly, these small malignancies induce a locally 
defined antitumor immune response (Ehlers & Schott 
2014). This hypothesis certainly needs investigation in 
pediatric population.
Studies in adults have found that PTC patients 
with coexisting Hashimoto’s thyroiditis tend to display 
specific features (Dvorkin et al. 2013; Jara et al. 2013; 
Kwon et al. 2014; Zhang et al. 2014; Iliadou et al. 2015; 
Noureldine & Tufano 2015). They are likely to be young 
women, with less aggressive disease, less frequent nodal 
metastases, less likely to develop recurrence, and have a 
higher survival rate (Dvorkin et al. 2013; Jara et al. 2013; 
Kwon et al. 2014; Zhang et al. 2014; Iliadou et al. 2015; 
Noureldine & Tufano 2015). In children, in line with 
Iliadou et al. (2015) large pediatric study, we have also 
found that patients with PTC AIT (+) vs. PTC AIT (–) 
were older, females (75%) dominated and PTC nodules 
were smaller. Additionally in our study we have found 
PTMC in 41.6 % of cases of PTC AIT (+) and higher 
TSH levels , however without an overt hypothyroiditis. 
The earlier diagnosis of smaller PTC lesions in AIT (+) 
than in AIT (–) children was possible due to more fre-
quent monitoring of patients with diagnosis of AITD or 
with AIT who are followed up with repeated US imag-
ing (Iliadou et al. 2015). 
In our PTC AIT (+) cohort we have also found local 
and distant metastases in the lymph nodes and in the 
lungs. Additionally what should be underlined is the 
fact that in 40% of PTMC AIT (+) metastases in lymph 
nodes were found including one patient with PTMC of 
9 x 8 x 8 mm with metastases found in as many as 13/29 
of lymph nodes assessed. Also in PTMC we observed 
one case of intrathyroidal invasion with multinodular-
ity (both lesions as small as 7 and 2 mm). Therefo re, in 
contrast to adult studies we are convinced that PTC and 
also PTMC in AIT (+) patients is not less aggressive 
disease than in AIT (–) pediatric patients (Iliadou et al. 
2015). In Iliadou et al. (2015) pediatric PTC study no 
better outcome of DTC was observed in regard to the 
absence or presence of AIT and additionally in patients 
with AIT and DTC more frequently invasive DTC with 
intrathyroidal infiltration and familial PTC were found. 
We are convinced that both in microPTC and macro 
PTC total thyroidectomy with lymph node verification 
should be performed in accordance to current recom-
mendations (Niedziela et al. 2016). On the other hand 
in early detected nodules as small as 11, 10, 7 and 6 mm 
for the first time we did not find lymph node involve-
ment what had an impact on the further therapy of our 
patients enabling the escape from 131 I therapy.
A limitation of the present study is a small number 
of patients. Multi-center transition studies involving 
both pediatric and adult patients are needed to evaluate 
disease course and thyroid ultrasound data especially in 
the light of controversies regarding ultrasound evalua-
tion of AIT patients. According to previous recommen-
dations thyroid ultrasound scan in children with AIT 
as not changing the treatment, clinical course or out-
come, should not be indicated routinely (de Vries et al. 
2009) and according to current guidelines ultrasound 
assessment should be performed annually in children 
with AIT (Niedziela et al. 2016). Due to high coinci-
dence of PTC with AIT in children we are positive that 
all patients with AIT should have thyroid ultrasound 
repeated at least annually to detect as small PTC as 
possible, before invasion to lymph nodes starts, thus 
enabling escape from 131I therapy, that stands in line 
with current recommendations (Niedziela et al. 2016, 
Januś et al. 2017).
CONCLUSION
Frequent coexistence of PTC and AIT underlines the 
need of ultrasound monitoring of patients with AIT 
and referral for FNAB if nodular goiter is detected.
Patients with autoimmune thyroiditis – euthyroid with 
raised aTPO, aTG or TRab autoantibodies present in 
the serum as well as patients with AITD without overt 
hypothyroiditis in both cases with normoechogenic 
thyroid gland on US imaging should be followed up 
with at least annual US assessment.
The lack of microcalcifications or increased vascu-
larisation in a solid thyroid nodule is not a criterion of 
disqualifying from FNAB in children. All solid thyroid 
nodules should be referred for ultrasound verification 
in a tertiary thyroid department and finally referred for 
FNAB verification.
In patients with AIT the natural course of PTC and 
also microPTC is not less aggresive than in patients with 
PTC AIT (–). As in 40 % of children with microPTC the 
metastases in lymph nodes were found in all children 
with PTC (micro and macroPTC) total thyroidectomy 
with lymph node verifications should be the treatment 
of choice.
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